Progress in Medicinal Chemistry: Volume 29
G. P. Ellis · D.K. Luscombe
Mas 1992 · Progress in Medicinal Chemistry Ibhuku elingu-29 · Elsevier
I-Ebook
349
Amakhasi
family_home
Kufanelekile
info
reportIzilinganiso nezibuyekezo aziqinisekisiwe Funda Kabanzi
Mayelana nale ebook
The 29th volume of the series presents yet again, an exemplary survey of a wide range of current topics in medicinal chemistry and pharmacology. Eight expert reviews emphasize the relationships between chemical structure and pharmacological activity. These detailed discussions of some of the most exciting developments in the field today, will prove of great value to future research. The book begins with a study of anti-inflammatory activities of 5-lipoxygenase inhibitors, followed by an overview of the antiarrhythmic therapeutic possibilities offered by Class III electrophysiological agents. Structures and activities of some opioid ligands are surveyed, and the investigation into pharmacologically active pyridazine derivatives is continued. Dopamine D2 receptor agonists offer exciting therapeutic potential, as do ondansetron and related 5-HT 3 antagonists. The herbal origin of many modern drugs is yet again reflected in a survey of the herb feverfew. The volume concludes, as it began, with enzyme inhibition - in this case concerning synthetic inhibitors of interstitial collagenases.
Nikeza le ebook isilinganiso
Sitshele ukuthi ucabangani.
Ulwazi lokufunda
Amasmathifoni namathebulethi
Faka uhlelo lokusebenza lwe-Google Play Amabhuku lwe-Android ne-iPad/iPhone. Livunyelaniswa ngokuzenzakalela ne-akhawunti yakho liphinde likuvumele ukuthi ufunde uxhunywe ku-inthanethi noma ungaxhunyiwe noma ngabe ukuphi.
Amakhompyutha aphathekayo namakhompyutha
Ungalalela ama-audiobook athengwe ku-Google Play usebenzisa isiphequluli sewebhu sekhompuyutha yakho.
Ama-eReaders namanye amadivayisi
Ukuze ufunde kumadivayisi e-e-ink afana ne-Kobo eReaders, uzodinga ukudawuniloda ifayela futhi ulidlulisele kudivayisi yakho. Landela imiyalelo Yesikhungo Sosizo eningiliziwe ukuze udlulise amafayela kuma-eReader asekelwayo.
